CRL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Charles River Laboratories International Inc (CRL) is not a strong buy for a beginner, long-term investor at this time. While the technical indicators show some bullish momentum, the financial performance and analyst sentiment suggest mixed growth prospects. The lack of significant positive catalysts, combined with neutral trading sentiment and no recent AI Stock Picker or SwingMax signals, makes it prudent to hold off on buying this stock for now.
The technical indicators suggest a bullish trend. The MACD is positive and expanding, the RSI is neutral at 66.862, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 180.732), with the next resistance at 186.186.
The MACD and moving averages indicate bullish momentum. Gross margin and EPS have shown improvement YoY.
Net income remains negative despite an improvement. Analyst ratings have been largely neutral or downgraded, with price targets lowered by multiple firms citing slower organic growth and lower free cash flow. No recent news or significant trading trends from insiders or hedge funds.
In Q4 2025, revenue dropped by -0.83% YoY to $994.23M. Net income improved by 28.21% YoY but remains negative at -$276.56M. EPS increased by 33.18% YoY to -5.62, and gross margin improved to 30.96%, up 11.49% YoY.
Analyst sentiment is mixed. While some firms maintain a Buy or Outperform rating, most have lowered their price targets, citing concerns about slower growth, lower free cash flow, and industry challenges. The current price of $181.32 is near the revised targets of $175-$200 from several analysts.
